Valeritas Announces that V-Go® Insulin Delivery Device has Launched in Australia
Share:
BRIDGEWATER, N.J., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch for patients with diabetes, today announced V-Go has launched and is now available in Australia through its previously disclosed exclusive distribution agreement with AMSL Diabetes.
“We are pleased to announce V-Go Wearable Insulin Delivery device is now available for patients with type 2 diabetes in Australia,” said Valeritas CEO, John Timberlake. “Australia is the second and largest country outside of the United States in which our flagship product V-Go has been launched, and we are excited V-Go will be demonstrated to physicians and patients during the Australia Diabetes Society meeting in Adelaide this week.”
Through the distribution agreement, Valeritas will retain responsibility for product development, regulatory approval, quality management, and manufacturing while AMSL Diabetes will be responsible for sales, marketing, customer support, and distribution activities in Australia.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
More information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.
About AMSL
AMSL is an affiliated private entity operating exclusively in Australia and has been involved in the provision of hi-tech medical devices and pharmaceuticals since the early 1980s. The company has been involved in the Australia diabetes arena for many years and has introduced many innovations in the fields of insulin delivery and blood glucose monitoring systems that have enabled thousands of people living with diabetes to enjoy a better quality of life and reduce their risk of long-term complications.
Investor Contacts:
Lynn Pieper Lewis or Greg Chodaczek
Gilmartin Group
646-924-1769
ir@valeritas.com
Media Contact:
Kevin Knight
Knight Marketing Communications, Ltd.
206-451-4823
pr@valeritas.com
